Abemaciclib
Abemaciclib is a pharmaceutical drug with 193 clinical trials. Currently 100 active trials ongoing. Historical success rate of 70.1%.
Success Metrics
Based on 54 completed trials
Phase Distribution
Phase Distribution
78
Early Stage
79
Mid Stage
26
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
64.3%
54 of 84 finished
35.7%
30 ended early
100
trials recruiting
193
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
SRS & Abemaciclib w/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain Metastases
Study of AVZO-021 in Patients With Advanced Solid Tumors
Clinical Trials (193)
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
SRS & Abemaciclib w/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain Metastases
Study of AVZO-021 in Patients With Advanced Solid Tumors
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
Genetic Testing in Guiding Treatment for Patients With Brain Metastases
Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer
A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Imlunestrant/Abemaciclib/Selinexor in Ovarian and Endometrial
A Phase 1 Study of Neoadjuvant Abemaciclib in Combination With Radiation Therapy for Liposarcomas
Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas
ALPINE: Maintenance Letrozole/Abemaciclib
Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca
Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 193